Semaglutide is a selective mono GLP-1 receptor agonist, whereas Tirzepatide is a dual GIP and GLP-1 receptor agonist.
| Feature / Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 only (Mono Agonist) | GIP + GLP-1 (Dual Agonist) |
| FDA Regulatory Status | Approved (Ozempic / Wegovy) | Approved (Mounjaro / Zepbound) |
| Elimination Half-Life | 7 days (165 hours) | 5 days (120 hours) |
| Starting Research Dose | 0.25 mg / week | 2.5 mg / week |
| Max Clinical Dose | 2.4 mg / week | 15.0 mg / week |
| Avg Weight Loss (Trial Data) | ~15% at 68 weeks (STEP-1) | ~20.9% at 72 weeks (SURMOUNT-1) |
| Estimated Monthly Cost | Moderate ($40 - $90/mo) | Higher ($90 - $180/mo) |
| Best Researched For | Standard glycemic & weight protocols | Maximum metabolic & weight efficacy |
Access chemical profile, half-life parameters, and U-100 reconstitution calculator.
Access chemical profile, half-life parameters, and U-100 reconstitution calculator.
Semaglutide is a selective mono GLP-1 receptor agonist, whereas Tirzepatide is a dual GIP and GLP-1 receptor agonist. In preclinical and clinical research trials, comparing receptor affinity, half-life clearance, and synthesis purity standards is critical for determining appropriate research protocols.
In scientific literature, certain peptide pairs (such as BPC-157 + TB-500, or CJC-1295 + Ipamorelin) exhibit complementary signaling pathways and are frequently studied together in stack protocols.
